Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia
- 1 November 2014
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 237 (1) , 140-145
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Statin diabetogenicity: guidance for cliniciansCardiovascular Diabetology, 2013
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialThe Lancet, 2012
- Are statins diabetogenic?Current Opinion in Cardiology, 2011
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin TherapyJAMA, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsThe Lancet, 2009
- Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessmentThe Lancet, 2006
- Intensive Integrated Therapy of Type 2 DiabetesDiabetes, 2004
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003